XML 164 R109.htm IDEA: XBRL DOCUMENT
v3.6.0.2

Investments in Variable Interest Entities (Details) - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended
--- | --- | ---
Dec. 31, 2015 | Sep. 30, 2015 | Mar. 31, 2014 | Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014
Variable Interest Entity [Line Items] |  |  |  |  |  |
Net (loss) income attributable to noncontrolling interests, net of tax |  |  |  | $ (7.1) | $ 46.2 | $ 6.8
Investment in Variable Interest Entities (Textual) |  |  |  |  |  |
Investment in biotechnology companies that are determined to be unconsolidated variable interest entities | $ 29.2 |  |  | 47.4 | 29.2 |
Neurimmune |  |  |  |  |  |
Variable Interest Entity [Line Items] |  |  |  |  |  |
Net (loss) income attributable to noncontrolling interests, net of tax |  | $ 60.0 |  |  |  |
Investment in Variable Interest Entities (Textual) |  |  |  |  |  |
Remaining potential development milestone payments and royalties on commercial sales under the terms of collaboration agreement |  |  |  | $ 275.0 |  |
Percentage of funding for R&D cost required in support of the collaboration agreement |  |  |  | 100.00% |  |
Rodin Therapeutics |  |  |  |  |  |
Investment in Variable Interest Entities (Textual) |  |  |  |  |  |
Payments to acquire interest in peferred stock of an affiliates | 8.0 |  |  |  |  |
In-process research and development | 8.7 |  |  |  |  |
Minority interest in our stockholder's equity | $ 10.9 |  |  |  | $ 10.9 |
Ataxion |  |  |  |  |  |
Investment in Variable Interest Entities (Textual) |  |  |  |  |  |
Payments to acquire interest in peferred stock of an affiliates |  |  | $ 1.6 |  |  |
In-process research and development |  |  | $ 3.5 |  |  |

X
- Definition Investment in biotechnology companies that are determined to be unconsolidated variable interest entities. + References No definition available. + Details
Name: | biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Investment in Variable Interest Entities. + References No definition available. + Details
Name: | biib_InvestmentInVariableInterestEntitiesTextualAbstract
Namespace Prefix: | biib_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Expected total payments including upfront and milestone payments as well as the greater of an annual maintenance fee or usage-based royalty payments under the terms of collaboration agreement. + References No definition available. + Details
Name: | biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Research and development cost in support of the collaboration agreement. + References No definition available. + Details
Name: | biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement
Namespace Prefix: | biib_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of Net Income (Loss) attributable to noncontrolling interest. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4J -URI http://asc.fasb.org/extlink&oid=65897068&loc=SL4591551-111686 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1A -Subparagraph (a)(2) -URI http://asc.fasb.org/extlink&oid=64809438&loc=SL4573702-111684 + Details
Name: | us-gaap_NetIncomeLossAttributableToNoncontrollingInterest
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Portion of equity (net assets) in a variable interest entity (VIE) not attributable, directly or indirectly, to the parent entity. That is, this is the portion of equity in a VIE that is attributable to the noncontrolling interest (previously referred to as minority interest). + References No definition available. + Details
Name: | us-gaap_NoncontrollingInterestInVariableInterestEntity
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585 + Details
Name: | us-gaap_ResearchAndDevelopmentInProcess
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_VariableInterestEntityLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_NeurimmuneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_RodinTherapeuticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_AtaxionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |